Specific inhibitors of growth-promoting cytokines such as IFNAR antibodies (10, 18) or infusing suppressive cytokines such as IL-10 might be better strategies than non-specific inhibition with JAK inhibitors for therapeutic manipulation of cytokines in CLL. This evidence concerns the gene IFNAR1 and B-cell chronic lymphocytic leukemia.